4.4 Review

The Roles of Xenobiotic Receptors: Beyond Chemical Disposition

期刊

DRUG METABOLISM AND DISPOSITION
卷 46, 期 9, 页码 1361-1371

出版社

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/dmd.118.081042

关键词

-

资金

  1. National Institutes of Health National Institute of General Medical Sciences [GM107058, GM121550]

向作者/读者索取更多资源

Over the past 20 years, the ability of the xenobiotic receptors to coordinate an array of drug-metabolizing enzymes and transporters in response to endogenous and exogenous stimuli has been extensively characterized and well documented. The constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) are the xenobiotic receptors that have received the most attention since they regulate the expression of numerous proteins important to drug metabolism and clearance and formulate a central defensive mechanism to protect the body against xenobiotic challenges. However, accumulating evidence has shown that these xenobiotic sensors also control many cellular processes outside of their traditional realms of xenobiotic metabolism and disposition, including physiologic and/or pathophysiologic responses in energy homeostasis, cell proliferation, inflammation, tissue injury and repair, immune response, and cancer development. This review will highlight recent advances in studying the noncanonical functions of xenobiotic receptors with a particular focus placed on the roles of CAR and PXR in energy homeostasis and cancer development.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Interleukin-20 exacerbates acute hepatitis and bacterial infection by downregulating IκBζ target genes in hepatocytes

Yong He, Dechun Feng, Seonghwan Hwang, Bryan Mackowiak, Xiaolin Wang, Xiaogang Xiang, Robim M. Rodrigues, Yaojie Fu, Jing Ma, Tianyi Ren, Yeni Ait-Ahmed, Mingjiang Xu, Suthat Liangpunsakul, Bin Gao

Summary: IL-20 selectively inhibits hepatic IL-6 production rather than exerting IL-10-like broad anti-inflammatory properties. Unlike IL-22, IL-20 aggravates acute hepatitis and bacterial infection. Thus, anti-IL-20 therapy could be a promising option to control acute hepatitis and bacterial infection.

JOURNAL OF HEPATOLOGY (2021)

Article Chemistry, Multidisciplinary

Research and Education Needs for Complex Generics

Sydney Stern, Jill Coghlan, Vishalakshi Krishnan, Sam G. Raney, Andrew Babiskin, Wenlei Jiang, Robert Lionberger, Xiaoming Xu, Anna Schwendeman, James E. Polli

Summary: Complex generics are generic drug products with complex characteristics, such as complex active ingredients, formulations, and routes of delivery, making them challenging to develop. The FDA established the Center for Research on Complex Generics to address these challenges, conducting a survey to prioritize research and educational initiatives for developing complex generics.

PHARMACEUTICAL RESEARCH (2021)

Review Pharmacology & Pharmacy

Clinical Relevance of the Constitutive Androstane Receptor

Sydney Stern, Ritika Kurian, Hongbing Wang

Summary: This review focuses on the role of the constitutive androstane receptor (CAR) in metabolic disorders and cancer development. CAR, which is known for its involvement in drug metabolism and detoxification, has also been found to regulate glucose, lipid, and bile acid homeostasis as well as cell proliferation and tissue repair.

DRUG METABOLISM AND DISPOSITION (2022)

Article Pharmacology & Pharmacy

17α-Hydroxyprogesterone Caproate Inhibits Cytokine Production via Suppression of NF-κB Activation

Tao Hu, Chengjifu Tang, Sydney Stern, Luan Yang, Tom Du

Summary: The synthetic progestogen 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been found to inhibit cytokine production in COVID-19 patients, reducing clinical symptoms. This study provides pharmacological evidence supporting the potential use of 17-OHPC in treating cytokine release syndrome associated with COVID-19.

FRONTIERS IN PHARMACOLOGY (2022)

Article Medicine, Research & Experimental

Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment

Sydney Stern, Dongdong Liang, Linhao Li, Ritika Kurian, Caitlin Lynch, Srilatha Sakamuru, Scott Heyward, Junran Zhang, Kafayat Ajoke Kareem, Young Wook Chun, Ruili Huang, Menghang Xia, Charles C. Hong, Fengtian Xue, Hongbing Wang

Summary: CN06 is a dual activator of CAR and Nrf2, enhancing the bioactivation of CPA and decreasing the cytotoxicity of DOX in vitro. In a multicellular coculture model, CN06 increased the toxicity of CPA/DOX towards TNBC cells, while protecting cardiomyocytes from DOX-induced cardiotoxicity by selectively activating Nrf2-antioxidant signaling.

JCI INSIGHT (2022)

Article Substance Abuse

Hepatic CYP2B10 is highly induced by binge ethanol and contributes to acute-on-chronic alcohol-induced liver injury

Bryan Mackowiak, Mingjiang Xu, Yuhong Lin, Yukun Guan, Wonhyo Seo, Ruixue Ren, Dechun Feng, Jace W. Jones, Hongbing Wang, Bin Gao

Summary: The study found that mice chronically fed with ethanol responded less severely to multiple binge ethanol consumption compared to a single binge. The upregulation of the Cyp2b10 gene after binge ethanol intake can indirectly modify ethanol metabolism and reduce acute-on-chronic ethanol-induced liver injury.

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH (2022)

Review Oncology

Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts

Silvia Stacchiotti, Hans Roland Duerr, Inga-Marie Schaefer, Klaus Woertler, Rick Haas, Annalisa Trama, Augusto Caraceni, Jyoti Bajpai, Giacomo Giulio Baldi, Nicholas Bernthal, Jean-Yves Blay, Kjetil Boye, Javier-Martin Broto, Wei-Wu Tom Chen, Paolo Angelo Dei Tos, Jayesh Desai, Stephan Emhofer, Mikael Eriksson, Alessandro Gronchi, Hans Gelderblom, Jendrik Hardes, Wolfgang Hartmann, John Healey, Antoine Italiano, Robin L. Jones, Akira Kawai, Andreas Leithner, Herbert Loong, Eric Mascard, Carlo Morosi, Nadine Otten, Emanuela Palmerini, Shreyaskumar R. Patel, Peter Reichardt, Brian Rubin, Piotr Rutkowski, Claudia Sangalli, Kathrin Schuster, Beatrice M. Seddon, Morena Shkcodra, Eric L. Staals, William Tap, Matt van de Rijn, Kirsten van Langevelde, Filip M. M. Vanhoenacker, Andrew Wagner, Lisette Wiltink, Sydney Stern, Michiel Van de Sande, Sebastian Bauer

Summary: Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive tumor that arises from the joints, bursa, and tendon sheaths. There are two types of TGCT: nodular and diffuse, with the former exhibiting a slow disease course and the latter showing locally aggressive behavior. Although not life-threatening, TGCT can cause chronic pain and negatively impact function and quality of life. CSFR1 inhibitors are effective in treating TGCT but are not widely available. The lack of guidelines and uncertainty in selecting appropriate therapy lead to inconsistent adoption of new treatments and suboptimal outcomes for patients. A global consensus meeting was held in June 2022 to develop evidence-based recommendations for the optimal management of TGCT.

CANCER TREATMENT REVIEWS (2023)

Editorial Material Gastroenterology & Hepatology

Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction

Bryan Mackowiak, Bin Gao

HEPATOLOGY (2023)

Review Cell Biology

Microphysiological Models for Mechanistic-Based Prediction of Idiosyncratic DILI

Sydney Stern, Hongbing Wang, Nakissa Sadrieh

Summary: Drug-induced liver injury (DILI) is a major concern in the pharmaceutical industry and global health due to its high attrition rates and complex pathogenesis. In vitro co-culture models that incorporate the immune system have shown promise in investigating idiosyncratic DILI (iDILI). Human-based 3D multicellular models have been developed to mimic the hepatic microenvironment and provide a more accurate representation of iDILI. However, more research is needed to harmonize and compare the characteristics of these models, as well as address challenges such as disease-related endpoints and multi-cellular mechanisms.
Article Gastroenterology & Hepatology

Dexamethasone mitigates remdesivir-induced liver toxicity in human primary hepatocytes and COVID-19 patients

Kaiyan Liu, Sydney Stern, Emily L. Heil, Linhao Li, Rula Khairi, Scott Heyward, Hongbing Wang

Summary: This study characterized the hepatotoxicity of Remdesivir (RDV) and its interaction with dexamethasone (DEX) in the treatment of hospitalized COVID-19 patients. The findings showed that RDV has hepatotoxic effects in vitro, but co-treatment with DEX can partially reverse the cytotoxic responses. Furthermore, the combination of RDV and DEX was associated with a reduced likelihood of elevated serum AST and ALT levels in COVID-19 patients compared to RDV alone.

HEPATOLOGY COMMUNICATIONS (2023)

Review Substance Abuse

Alcohol metabolism in alcohol use disorder: a potential therapeutic target

Taylor Lehner, Bin Gao, Bryan Mackowiak

Summary: This review explores the effects of ethanol metabolism, specifically alcohol dehydrogenase and aldehyde dehydrogenase 2 (ALDH2), on drinking behaviors. The role of genetic polymorphisms in these enzymes in altering the risk for alcohol use disorder (AUD) is discussed, as well as potential interventions that modulate ethanol metabolism. The paper highlights the use of disulfiram, RNAi strategies, and kudzu/isoflavones to influence ALDH2 activity and decrease drinking behavior, while also mentioning other metabolism-centric therapeutic targets.

ALCOHOL AND ALCOHOLISM (2023)

Article Pharmacology & Pharmacy

Creating a Roadmap to Quantitative Systems Pharmacology-Informed Rare Disease Drug Development: A Workshop Report

Jane P. F. Bai, Audra L. Stinchcomb, Jie Wang, Justin Earp, Sydney Stern, Robert N. Schuck

Summary: The Accelerating Rare Disease Cures (ARC) program of the US FDA aims to develop and use regulatory and scientific tools for rare disease drug development. To facilitate this, a virtual workshop was hosted by the FDA in collaboration with the University of Maryland, discussing the potential utility of quantitative systems pharmacology (QSP) and proposing a roadmap for its implementation in this field.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Medicine, Research & Experimental

Distinct histopathological phenotypes of severe alcoholic hepatitis suggest different mechanisms driving liver injury and failure

Jing Ma, Adrien Guillot, Zhihong Yang, Bryan Mackowiak, Seonghwan Hwang, Ogyi Park, Brandon J. Peiffer, Ali Reza Ahmadi, Luma Melo, Praveen Kusumanchi, Nazmul Huda, Romil Saxena, Yong He, Yukun Guan, Dechun Feng, Pau Sancho-Bru, Mengwei Zang, Andrew MacGregor Cameron, Ramon Bataller, Frank Tacke, Zhaoli Sun, Suthat Liangpunsakul, Bin Gao

Summary: Two distinct patterns of intrahepatic neutrophil infiltration are observed in severe alcoholic hepatitis (SAH) patients, suggesting separate mechanisms driving liver injury.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Gastroenterology & Hepatology

MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases

Xiaolin Wang, Yong He, Bryan Mackowiak, Bin Gao

Summary: MicroRNAs are small, non-coding RNAs that play crucial roles in regulating liver functions and are associated with various liver diseases, making them promising for early diagnosis and treatment strategies. Continued research on miRNAs in the liver may lead to the identification of biomarkers and therapeutic targets for liver diseases in the future.
Article Pharmacology & Pharmacy

Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress

Ramon Martinez, Weiliang Huang, Ramin Samadani, Bryan Mackowiak, Garrick Centola, Lijia Chen, Ivie L. Conlon, Kellie Hom, Maureen A. Kane, Steven Fletcher, Paul Shapiro

Summary: This study identified a novel compound that exhibited biological activity in A375 melanoma cells with mutated BRAF (V600E) and had global effects on gene and protein levels. The compound interacted with ERK2, including forming a covalent adduct on cysteine 252 near the ERK/FXF (DEF) motif, selectively inhibiting ERK1/2-related functions. Furthermore, the compound inhibited proliferation of A375 cells through a ROS-dependent mechanism.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)

暂无数据